Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tianjin Pharmaceutical Da Ren Tang Group's revenue for the
three
months ended in Mar. 2026 was €190.2 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was €607.7 Mil.
Tianjin Pharmaceutical Da Ren Tang Group's Revenue per Share for the
three
months ended in Mar. 2026 was €0.25.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €0.79.
Warning Sign:
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd revenue per share has been in decline for the last 5 years.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Tianjin Pharmaceutical Da Ren Tang Group Revenue Related Terms
Tianjin Pharmaceutical Da Ren Tang Group Revenue Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tianjin Pharmaceutical Da Ren Tang Group Revenue Chart
Tianjin Pharmaceutical Da Ren Tang Group Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Tianjin Pharmaceutical Da Ren Tang Group's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tianjin Pharmaceutical Da Ren Tang Group Revenue vs Drug Manufacturers Industry
Tianjin Pharmaceutical Da Ren Tang Group Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €607.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) has a Revenue of €607.7 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Tianjin Pharmaceutical Da Ren Tang Group and its competitors.
Is Tianjin Pharmaceutical Da Ren Tang Group's Revenue too high?
Tianjin Pharmaceutical Da Ren Tang Group's current Revenue is €607.7 Mil. Overall, Tianjin Pharmaceutical Da Ren Tang Group has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tianjin Pharmaceutical Da Ren Tang Group's Revenue compare to ZTS?
Tianjin Pharmaceutical Da Ren Tang Group's Revenue of €607.7 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Drug Manufacturers company?
A good Revenue depends on the Drug Manufacturers industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Tianjin Pharmaceutical Da Ren Tang Group and its competitors. Tianjin Pharmaceutical Da Ren Tang Group's current Revenue is €607.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tianjin Pharmaceutical Da Ren Tang Group stock overvalued right now?
Based on GuruFocus' analysis, Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.37, compared to a current price of €2.40 — trading 75.2% above its estimated fair value. The current Revenue is €607.7 Mil. Tianjin Pharmaceutical Da Ren Tang Group's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ), the current Revenue is €607.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) Overvalued in 2026?
Based on GuruFocus' analysis, Tianjin Pharmaceutical Da Ren Tang Group stock appears to be overvalued.
The current stock price of €2.40 is trading 75.2% above its estimated GF Value™ of €1.37.
GuruFocus considers Tianjin Pharmaceutical Da Ren Tang Group to be Significantly Overvalued.
Key valuation signals for STU:2TZ:
Revenue: €607.7 Mil
GF Value™: €1.37 vs. price of €2.40 (75.2% above fair value)
No single metric tells the full story. See the STU:2TZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company is engaged in the production and sale of traditional Chinese medicine, Western medicine, healthcare products, and investment holding. It operates in two segments, namely the Chinese Medicine segment and the Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures Western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese medicine.
69GF Score
Get the complete analysis for STU:2TZ
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2TZ has been successfully added to your 
